BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 17
• 18
• 19
• 20
• 21
• 22
• 24
• 25
• 26
• 27
• 28
• 29
• 30

• Genedata Profiler Moves to High-Performance Clouds

  Genedata today announced that Genedata Profiler can now also be deployed in cloud environments such as Microsoft Azure and Amazon Web Services, additional to on-premises and private cloud environments.

  December 20, 2017

   · 

  3 min read
• 

  Business

  TARIS, Bristol-Myers Squibb Ink Phase 1b Collaboration

  In conjunction with this collaboration, Bristol-Myers Squibb also made an equity investment in TARIS.

  December 20, 2017

   · 

  24 min read
• Drug Development

  Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase I Study of ARO-AAT

  Pending approval, Arrowhead intends to proceed with AROAAT1001, a Phase 1 single and multiple ascending dose study to evaluate the safety, tolerability, pharmacokinetics, and effect of ARO-AAT on serum alpha-1 antitrypsin levels in healthy adult volunteers.

  December 20, 2017

   · 

  3 min read
• BioMidwest

  Aratana Therapeutics Granted Conditional License for a Canine Osteosarcoma Therapeutic

  Aratana today announced the USDA Center for Veterinary Biologics granted Aratana conditional licensure for Canine Osteosarcoma Vaccine, Live Listeria Vector for the treatment of dogs diagnosed with osteosarcoma, one year of age or older.

  December 20, 2017

   · 

  8 min read
• Drug Development

  Peloton Therapeutics Phase I Study of PT2385 Published in the Journal of Clinical Oncology Validates HIF-2α Antagonism for the Treatment of Kidney Cancer

  These data demonstrated PT2385, the first clinical stage antagonist of hypoxia inducible factor-2α (HIF-2α), has a favorable safety profile and is active in patients with heavily pretreated clear cell renal cell carcinoma (ccRCC).

  December 20, 2017

   · 

  5 min read
• Business

  ORIC Has Appointed Rich Heyman, PhD as Acting CEO and Leonard Reyno, MD as CMO

  Dr. Rich Heyman has over 25 years of biopharma experience and previously served as CEO of Seragon.

  December 20, 2017

   · 

  3 min read
• Business

  Acticor Biotech Announces Appointment of Dr Yannick Plétan as Chief Medical Officer

  He will report to Gilles Avenard, CEO of Acticor Biotech and be responsible for leading all clinical development and medical affairs at Acticor Biotech.

  December 20, 2017

   · 

  2 min read
• Pharm Country

  PENTAX Medical Announces Launch of First FDA-Cleared HD Duodenoscope With Disposable Distal Cap

  PENTAX Medical announced the U.S. launch of its new C.A.P. HD Duodenoscope, the first FDA-cleared duodenoscope with a disposable distal cap.

  December 20, 2017

   · 

  3 min read
• Drug Development

  Mesoblast’s Phase III Trial in Children With Acute Graft Versus Host Disease Completes Enrollment

  Top-line results are expected in Q1 2018.

  December 20, 2017

   · 

  5 min read
• 

  Business

  Nuritas Raises €16 Million in Series A Funding Using Artificial Intelligence to Unlock Bioactive Peptides to Address Societal Issues

  Nuritas today announced the close of a circa €16 million Series A funding round led by Chicago-based Cultivian Sandbox Ventures.

  December 20, 2017

   · 

  4 min read